DrugPatentWatch Database Preview
CAPITAL SOLEIL 15 Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Capital Soleil 15, and what generic alternatives are available?
The generic ingredient in CAPITAL SOLEIL 15 is avobenzone; ecamsule; octocrylene. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the avobenzone; ecamsule; octocrylene profile page.
Summary for CAPITAL SOLEIL 15
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 47 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CAPITAL SOLEIL 15 at DailyMed |
US Patents and Regulatory Information for CAPITAL SOLEIL 15
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loreal Usa | CAPITAL SOLEIL 15 | avobenzone; ecamsule; octocrylene | CREAM;TOPICAL | 021501-001 | Oct 2, 2006 | OTC | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
